Daily Stock Analysis, DBVT, DBV Technologies SA, priceseries

DBV Technologies SA. Daily Stock Analysis
Stock Information
Open
10.05
Close
9.95
High
10.06
Low
9.90
Previous Close
10.05
Daily Price Gain
-0.10
YTD High
11.13
YTD High Date
Jul 5, 2019
YTD Low
5.77
YTD Low Date
Jan 23, 2019
YTD Price Change
2.96
YTD Gain
42.35%
52 Week High
25.77
52 Week High Date
Sep 21, 2018
52 Week Low
3.60
52 Week Low Date
Dec 20, 2018
52 Week Price Change
-7.34
52 Week Gain
-42.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 6. 2017
36.00
Aug 8. 2017
44.75
23 Trading Days
24.32%
Link
LONG
Dec 15. 2017
21.93
Jan 16. 2018
25.57
19 Trading Days
16.62%
Link
LONG
Aug 17. 2018
18.80
Sep 5. 2018
21.16
12 Trading Days
12.55%
Link
LONG
Sep 7. 2018
21.88
Sep 26. 2018
23.76
13 Trading Days
8.57%
Link
LONG
Apr 3. 2019
7.84
Apr 18. 2019
8.72
11 Trading Days
11.20%
Link
LONG
Apr 23. 2019
9.10
May 7. 2019
9.59
10 Trading Days
5.41%
Link
LONG
Jul 1. 2019
8.67
Jul 16. 2019
10.08
10 Trading Days
16.22%
Link
Company Information
Stock Symbol
DBVT
Exchange
NasdaqGS
Company URL
http://www.dbv-technologies.com
Company Phone
33(0)155427878
CEO
Pierre-Henri Benhamou
Headquarters
-
Business Address
177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, FRANCE 92120
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001613780
About

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. The company focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. It has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Description

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.